Shares of NuVasive (NUVA -0.9%) aren't getting much help today from upgrade to Outperform at Wells Fargo as the stock struggles to break through key technical resistance levels. Wells cites improvements in the spine market and the company's conservative 2012 guidance for the upgrade. The firm alos raised its price target range to $29 - $31 from $17 - $18.
Shares of NuVasive (NUVA -0.9%) aren't getting much help today from upgrade to Outperform at...
From other sites
Video at CNBC.com (Jul 13, 2016)
Video at CNBC.com (Jun 3, 2016)
at CNBC.com (Oct 4, 2012)
at CNBC.com (Oct 3, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs